The US Food and Drug Administration has approved Pernix Therapeutics’ (Nasdaq: PTX) Treximet (sumatriptan and naproxen sodium) for use in pediatric patients 12 years of age and older for the acute treatment of migraine with or without aura.The news pushed the firm’s share up 7% to $6.91 in afternoon trading on Friday.
Treximet is the first approved combination prescription medicine, and the first to contain sumatriptan, for the treatment of acute migraine attacks in pediatric patients. The two medicines – sumatriptan and naproxen sodium – in combination provide more effective, sustained control of the pain and associated symptoms of migraine compared to either medicine taken alone.
Pernix acquired US rights to Treximet from UK pharma major GlaxoSmithKline (LSE: GSK) a year ago, in a deal that cost it $250 million upfront and an agreement to pay royalties of 18% on future sales (The Pharma Letter May 15, 2015). GSK’s Treximet net US sales in 2013 were $78.7 million. In the first quarter of this year, Treximet revenues were $21 million out of total sales of $33.9 million, but the company forecast total sales in 2015 would be between $220 and $250 million, with revised expectations for Treximet, and with important investments in the Zohydro ER franchise
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze